Novel quinoline compounds active in cancer cells through coupled DNA methyltransferase inhibition and degradation

Article abstract of DOI:10.3390/cancers12020447

DNA methyltransferases (DNMTs) play a relevant role in epigenetic control of cancer cell survival and proliferation. Since only two DNMT inhibitors (azacitidine and decitabine) have been approved to date for the treatment of hematological malignancies, the development of novel potent and specific inhibitors is urgent. Here we describe the design, synthesis, and biological evaluation of a new series of compounds acting at the same time as DNMTs (mainly DNMT3A) inhibitors and degraders. Tested against leukemic and solid cancer cell lines, 2a–c and 4a–c (the last only for leukemias) displayed up to submicromolar antiproliferative activities. In HCT116 cells, such compounds induced EGFP gene expression in a promoter demethylation assay, confirming their demethylating activity in cells. In the same cell line, 2b and 4c chosen as representative samples induced DNMT1 and-3A protein degradation, suggesting for these compounds a double mechanism of DNMT3A inhibition and DNMT protein degradation.

Full text of DOI:10.3390/cancers12020447

Article
Novel Quinoline Compounds Active in Cancer Cells
through Coupled DNA Methyltransferase
Inhibition and Degradation
1,2,†
1,†
1
2
3
Clemens Zwergel , Rossella Fioravanti , Giulia Stazi , Federica Sarno , Cecilia Battistelli ,
1
2
4
4
Annalisa Romanelli , Angela Nebbioso , Eduarda Mendes , Alexandra Paulo ,
3,5
3,5,6
7
7,8
Raffaele Strippoli , Marco Tripodi , Dany Pechalrieu , Paola B. Arimondo
,
9
9
9,10,
Teresa De Luca , Donatella Del Bufalo , Daniela Trisciuoglio *,
Lucia Altucci , Sergio Valente * and Antonello Mai *
2
1,
1,
1
Department of Drug Chemistry and Technologies, Sapienza University of Rome, P. le A. Moro 5,
00185 Rome, Italy; clemens.zwergel@uniroma1.it (C.Z.); rossella.fioravanti@uniroma1.it (R.F.);
giulia.stazi@uniroma1.it (G.S.); annalisa.romanelli@uniroma1.it (A.R.)
Department of Precision Medicine, University of Studi della Campania Luigi Vanvitelli, Vico L. De
Crecchio 7, 80138 Naples, Italy; FEDERICA.SARNO@unicampania.it (F.S.);
angela.nebbioso@unicampania.it (A.N.); lucia.altucci@unicampania.it (L.A.)
Department of Molecular Medicine, Sapienza University of Rome, Viale Regina Elena 324,
00161 Rome, Italy; cecilia.battistelli@uniroma1.it (C.B); raffaele.strippoli@uniroma1.it (R.S.);
marco.tripodi@uniroma1.it (M.T.)
Research Institute for Medicines, Medicinal Chemistry Group, Faculty of Pharmacy, Universidade de
Lisboa, 1649ꢀ003 Lisbon, Portugal; ermendes@ff.ulisboa.pt (E.M.); mapaulo@ff.ulisboa.pt (A.P.)
National Institute for Infectious Diseases L. Spallanzani, IRCCS, Via Portuense, 292, 00149 Rome, Italy
Istituto Pasteur- Fondazione Cenci Bolognetti, Department of Molecular Medicine, Sapienza Università di
Roma, 00185 Rome, Italy
2
3
4
5
6
7
8
9
ETaC CNRS FRE3600, LMBE, 118 route de Narbonne, 31062 Toulouse, France;
dany.pechalrieu@gmail.com (D.P.); Paola.ARIMONDO@cnrs.fr (P.B.A.)
Epigenetic Chemical Biology, Institute Pasteur, CNRS UMR3523, 28 rue du Docteur Roux,
75724 Paris, France
Preclinical Models and New Therapeutic Agents Unit, IRCCS-Regina Elena National Cancer Institute, Via
Elio Chianesi 53, 00144 Rome, Italy; teresa.deluca@ifo.gov.it (T.D.L.);
donatella.delbufalo@ifo.gov.it (D.D.B.)
Institute of Molecular Biology and Pathology, National Research Council (CNR), Via Degli Apuli 4,
00185 Rome, Italy
10
* Correspondence: daniela.trisciuoglio@uniroma1.it (D.T.); sergio.valente@uniroma1.it (S.V.);
antonello.mai@uniroma1.it (A.M.)
†
These authors contributed equally to this work.
Received: 22 December 2019; Accepted: 12 February 2020; Published: 14 February 2020
Abstract: DNA methyltransferases (DNMTs) play a relevant role in epigenetic control of cancer cell
survival and proliferation. Since only two DNMT inhibitors (azacitidine and decitabine) have been
approved to date for the treatment of hematological malignancies, the development of novel potent
and specific inhibitors is urgent. Here we describe the design, synthesis, and biological evaluation
of a new series of compounds acting at the same time as DNMTs (mainly DNMT3A) inhibitors and
degraders. Tested against leukemic and solid cancer cell lines, 2a–c and 4a–c (the last only for
leukemias) displayed up to submicromolar antiproliferative activities. In HCT116 cells, such
compounds induced EGFP gene expression in a promoter demethylation assay, confirming their
demethylating activity in cells. In the same cell line, 2b and 4c chosen as representative samples
Cancers 2020, 12, 447; doi:10.3390/cancers12020447
www.mdpi.com/journal/cancers

Cancers 2020, 12, 447
2 of 20
induced DNMT1 and -3A protein degradation, suggesting for these compounds a double
mechanism of DNMT3A inhibition and DNMT protein degradation.
Keywords: drug discovery; medicinal chemistry; DNA methyltransferase; enzyme inhibition;
protein degradation; apoptosis
1. Introduction
DNA methylation is one of the most extensively studied epigenetic marks, playing an important
role in genomic imprinting; DNA repair; X-chromosome inactivation; and silencing of
retrotransposons, repetitive elements, and tissue-specific genes. Both the hypo- and
hypermethylation of different genome regions play a crucial role in tumorigenesis [1]. For this reason,
focal hypermethylation has been intensively studied in cancer, as a causative factor of transcriptional
inactivation of tumor suppressor genes (TSG) [2]. Some TSGs, including GSTP1, MGMT, CDH1, P16,
RAR-β2, septin 9 (SEPT9), syndecan 2 (SDC2), cyclin-dependent kinase inhibitor 2A (CDKN2A), and
short stature homeobox 2 (SHOX2), have been validated to be silenced through DNA methylation in
various types of cancer [3]. DNA methylation occurs mainly in the context of CpG dinucleotides
clustered in CpG islands [4–6] and is governed by catalytically active DNA methyltransferase
(DNMT) enzymes, which methylate the 5-position of cytosine by using S-adenosyl-L-methionine
(SAM) as the cosubstrate. DNMT1 is responsible for DNA methylation by preserving the DNA
methylation pattern during the replication; DNMT3A and DNMT3B perform de novo DNA
methylation either on hemi methylated or unmethylated double stranded DNA; DNMT2 catalyzes
the methylation on tRNA, and is called TRDMT1; finally, DNMT3-Like protein (DNMT3L) does not
display catalytic activity but works as a regulatory factor in complex with DNMT3A and -B [7,8]. Like
for other epigenetic modifications, the reversibility of DNA methylation represents an interesting
therapeutic strategy, especially in cancer [9–11]. Hence, several studies clearly showed that the
DNMTs’ depletion by RNA interference is sufficient to provide TSGs re-expression and cell growth
arrest and to promote re-differentiation of several cancer cell types including lung, esophagus,
stomach, breast, cervix, brain, and head and neck cancer [10–12].
Two families of DNMT inhibitors (DNMTi) have been described so far as useful tools to
reactivate TSGs and to reprogram cancer cells towards growth arrest and death: the covalent,
irreversible nucleoside inhibitors and the non-nucleoside inhibitors [12,13]. Two nucleoside-like
DNMTi (5-azacytidine, 5-AZA, and 5-aza-2′-deoxycytidine, DAC, Figure 1) have been approved by
the FDA for clinical use against myelodysplastic syndromes and acute myeloid leukemia, but despite
their high efficacy, their use is limited by poor bioavailability, chemical instability, and severe side-
effects [13]. Fewer limitations are shown by guadecitabine [14] (Figure 1), a dinucleotide derivative
of DAC with better pharmacokinetic properties, currently under phase I/II clinical trials for the
treatment of either hematological or solid cancers, alone or in combination with other
chemotherapeutic agents [15]. Various natural and synthetic non-nucleoside inhibitors have been
reported recently, but even though they are less toxic than azanucleosides, they share low potency
and/or low specificity for DNMTs. Some natural compounds such as mahanine and laccaic acid A
have been recently reviewed as DNMTi capable of reactivating several TSGs [8,16]. Repositioning of
old drugs (i.e., hydralazine, in phase II clinical trials against solid cancers [3], and procainamide,
Figure 1) [16] or identification of new chemical entities such as RG-108 [17] and its naphthoylproline
analog [18], isoxazoline [19] and oxazoline [20] derivatives, and SGI-1027 [21] (Figure 1) provided the
structural bases for developing novel and more potent DNMTi. Furthermore, carbazoles (DC517)
[22], hydrazineylidenemethyl benzothiazoles (compound 17) [23], and some DNMT3A-selective
quinazolines (compound 14 [24] and compound 68 [25]) (Figure 1) enriched the recent literature on
DNMTi, but still need further studies for clinical development.

Cancers 2020, 12, 447
3 of 20
Figure 1. Known nucleoside and non-nucleoside DNMTs inhibitors.
In 2014, through a process of hit-to-lead optimization, we identified the meta-meta isomer of SGI-
1027, 1 (MC3343, Figure 2), as a non-nucleoside DNMTi more potent and selective than SGI-1027
toward other SAM-dependent methyltransferases [26–28]. Compound 1 displayed single-digit
micromolar potency against a panel of cancer cells including mouse medulloblastoma stem cells,
showing less toxicity than SGI-1027 in peripheral blood mononuclear cells [26]. Furthermore, 1
impaired tumor proliferation of osteosarcoma cells as well, by blocking cell cycle in G1 or G2/M
phases, and induced osteoblastic differentiation through specific re-expression of genes that regulate
this physiological process [28]. Together with 1 two other SGI-1027 analogues, the bis-quinoline 2
and the bis-pyrimidine 3 (Figure 2) [26] were disclosed as novel DNMTi that, although less potent
than 1 in biochemical and cellular assays, were considered structurally worthy of a next step of SAR
investigation. Last, the further SGI-1027 analogue
4 (MC3353, Figure 2), in which a
benzyloxycarbonyl (Z) group replaced the pyrimidine moiety, has been described by us to arrest cell
proliferation in lymphoma as well as in solid cancer cells at sub- to single digit micromolar
concentrations [29].

Cancers 2020, 12, 447
4 of 20
Figure 2. Regioisomers and analogues of SGI-1027 described by our research group.
Starting from these findings, we applied structural changes to 1 by pin-point methylene spacer
insertion at four different points of the molecule (1a–d) to increase its flexibility, and we transformed
the amide function of 1 into its reverse amide (1e) or the corresponding amine (1f) linkage (Figure
3A). Afterwards, we performed a regioisomeric study on the bis-quinoline 2, on the bis-pyrimidine
3, and on the Z group-containing 4 by synthesizing for each prototype the meta-para, meta-meta and
para-meta isomers (compounds 2a–c, 3a–c, and 4a–c, respectively) (Figure 3B). The newly synthesized
compounds 1a–f, 2a–c, 3a–c, and 4a–c were screened against human DNMT1 (hDNMT1) and the C-
terminal catalytic domain of human DNMT3A (hDNMT3A) to determine their inhibitory activities.
Then, all compounds were tested against U937 acute myeloid leukemia (AML) and HL60 acute
promyelocytic leukemia (APL) cell lines to detect their antiproliferative effect, and for the most potent
compounds (2a–c and 4a–c) the cell death mechanism (apoptosis through the sub-G1 peak, caspase
activation, and annexin V induction) in U937 cells was evaluated. Afterwards, 2a–c and 4a–c were
tested in a panel of solid cancer cell lines to ascertain their anticancer potential. To confirm that the
phenotypic effect observed in cancer cells is related to the activity of such compounds on DNMTs,
2a–c and 4a–c were evaluated in a promoter demethylating and gene re-expression (enhanced green
fluorescence protein (EGFP) induction) assay in HCT116 colorectal carcinoma cells. Moreover, since
a certain discrepancy between the biochemical and the antiproliferative cellular values of the most
potent compounds has been noted, selected compounds 2b and 4c were tested in HCT116 cells to
check their ability to degrade the DNMT proteins, highlighting the involvement of a proteasome-
dependent molecular mechanism for such protein.

Cancers 2020, 12, 447
5 of 20
Figure 3. (A) Chemical structures of novel analogues of 1 (compounds 1a–f, in red the changes with
respect to 1). (B) Chemical structures of the 2–4 regioisomers (2a–c, 3a–c, and 4a–c).
2. Results
2.1. Design and Synthesis of Quinoline-Based DNMTi
Compounds 1a–f, 2a–c, 3a–c, and 4a–c were prepared as summarized in Schemes 1 and 2.
Reaction of 4-chloroquinoline with ethyl 3-(aminomethyl)benzoate in the presence of sodium acetate
and water or, alternatively, with ethyl 2-(3-aminophenyl)acetate with aqueous 37% hydrochloric acid
(HCl) solution in ethanol furnished the ethyl esters 5 and 6, respectively, which underwent basic
hydrolysis to give the corresponding carboxylic acids 7 and 8. Further coupling of 7 and 8 with the
4
N -(3-aminophenyl)-6-methylpyrimidine-2,4-diamine 9 [26] led to 1a and 1b, respectively (Scheme
1A). Reaction of 3-nitrobenzylamine with 3-(quinolin-4-ylamino)benzoic acid 10 [26] or, alternatively,
with 4-chloro-6-methylpyrimidin-2-amine in the presence of N,N-diisopropylethylamine at 160 °C in
DMSO by microwave irradiation yielded the nitrophenyl derivatives 11 and 12, respectively, which
were in turn reduced with stannous chloride dihydrate and 37% HCl in ethanol to the corresponding
anilines 13 and 14. Final reaction of 13 with 4-chloro-6-methylpyrimidin-2-amine in the presence of
37% HCl in n-butanol or, alternatively, of 14 with 3-(quinolin-4-ylamino)benzoic acid 10 [26] in the
presence
of
triethylamine
and
benzotriazol-1-yl-oxytripyrrolidinophosphonium
hexafluorophosphate (PyBop) in dry DMF under N2 atmosphere furnished 1c and 1d, respectively
1
(Scheme 1B). The synthesis of the reverse amide 1e was accomplished by coupling two synthons, N -
(quinolin-4-yl) benzene-1,3-diamine 16 and 3-((2-amino-6-methylpyrimidin-4-yl) amino) benzoic
acid 18, in the presence of triethylamine and PyBop in dry DMF under N2 atmosphere. The diamine
16 was prepared by treating 4-chloroquinoline with 3-nitroaniline in the presence of 37% HCl in
ethanol and subsequent reduction of the nitro derivative 15 with stannous chloride dihydrate in 37%
HCl, while the acid 18 was obtained by reaction between 4-chloro-6-methylpyrimidin-2-amine and
ethyl 3-aminobenzoate in 37% HCl followed by alkaline hydrolysis of the resulting ethyl ester 17
(Scheme 1C). Finally, 1f was synthesized by treating 4-chloroquinoline with 3-aminobenzyl alcohol.
Further oxidation of the obtained intermediate 19 with manganese dioxide in anhydrous
4
tetrahydrofuran at 60 °C afforded the aldehyde 20 that, after reductive amination with N -(3-
aminophenyl)-6-methylpyrimidine-2,4-diamine
[26]
in
the
presence
of
sodium
triacetoxyborohydride in anhydrous dichloroethane, yielded the final amine 1f (Scheme 1D).

Cancers 2020, 12, 447
6 of 20
Scheme 1A–D. Synthesis of 1a–f. Reagents and conditions: (a) sodium acetate, H2O, reflux, 25%; (b)
2N potassium hydroxide, ethanol/H2O 1:1, rt, 12 h, 78% to 91%; (c) triethylamine, benzotriazol-1-yl-
oxytripyrrolidino phosphonium hexafluorophosphate (PyBop), dry DMF, N2 atmosphere, rt, 3 h, 36%;
(d)
37%
hydrochloric
acid,
ethanol,
80
°C,
1
h,
70%;
(e)
N-ethyl-N'-(3-
dimethylaminopropyl)carbodiimide hydrochloride (EDCI), triethylamine, dry DCM, room
temperature, 48 h, 36%; (f) stannous chloride dihydrate, 37% HCl, ethanol, 80 °C, 5 h, 62%; (g) 37%
HCl, n-butanol, 80 °C, 1 h, 46%; (h) N,N-diisopropylethylamine (DIPEA), DMSO, 160 °C, microwave
irradiation, 45 min, 80%; (i) manganese dioxide, dry THF, 60 °C, 12 h, 48%. (j) sodium
triacetoxyborohydride, dry DCE, reflux, 10 h, 50%.
The above reaction performed in the presence of triethylamine and PyBop in dry DMF under
nitrogen atmosphere was used to prepare the bis-quinoline (2a–c) and the bis-pyrimidine (3a–c)
regioisomers, through reaction of the appropriate synthons (3- and 4-(quinolin-4-ylamino)benzoic
1
acids (10, 21) [26] and N -(quinolin-4-yl)benzene-1,3- (16) and -1,4-diamine (22) [26] for 2a–c, Scheme
4
2A; 3- (18) and 4- (23) -((2-amino-6-methylpyrimidin-4-yl)amino)benzoic acids [26] and N -(3- and 4-
aminophenyl)-6-methylpyrimidine-2,4-diamines (9, 24) [26] for 3a–c, Scheme 2B). Finally, 10 and 21
were treated with 1,3- and 1,4-phenylendiamine to furnish the amidoanilines 25–27, which were in
turn acylated with benzyloxycarbonylchloride to afford the regioisomers 4a–c (Scheme 2C).

Cancers 2020, 12, 447
7 of 20
O
A
O
NH2
HN
HN
N
OH
+
HN
N
NH
N
HN
a
N
2a
2b
2c
(meta,para)
(meta, meta)
(para,meta)
10 (meta)
16
(meta)
(para)
21
(para)
22
O
O
B
NH2
HN
HN
OH
HN
NH
N
HN
a
N
N
N
N
+
H2N
N
H2N
N
H2N
H2N
N
3a
3b
3c
(meta,para)
(meta, meta)
(para,meta)
18
23
9
24
(meta)
(para)
(meta)
(para)
O
O
O
C
HN
HN
HN
OH NH2
HN
HN
N
NH
NH2
a
+
O
O
b
N
N
H2N
4a
4b
4c
(meta,para)
(meta, meta)
(para,meta)
10
21
(meta)
(para)
25
(meta,para)
26 (meta, meta)
27
(para,meta)
Scheme 2A–C. Synthesis of 2a–c, 3a–c and 4a–c. Reagents and conditions: (a) triethylamine, PyBop,
dry DMF, N
2
atmosphere, rt, 1–12 h. (b) benzyl chloroformate, triethylamine, dry THF, 0 °C, 2 h, 27%
to 75%.
2.2. Enzyme Assays and Antiproliferative Activities Against U937 AML and HL60 APL Cells
The new compounds 1a–f, 2a–c, 3a–c, and 4a–c were tested at 100 µM against human DNMT1
(hDNMT1), and at 32 µM against the C-terminal catalytic domain of human DNMT3A (hDNMT3A),
due to the greater sensitivity of hDNMT3A towards the relative prototypes, and their inhibitory
activities have been evaluated. Compounds 1–4 were used as reference controls. As expected, the
described new quinoline and pyrimidine derivatives were in general more potent against hDNMT3A
than against hDNMT1 (Figure 4).
Figure 4. Percentage of inhibiting activities of 1a–f, 2a–c, 3a–c, and 4a–c against hDNMT1 (compounds
tested at 100 µM) and hDNMT3A (compounds tested at 32 µM). Compounds 1–4 were used as
reference drugs.
The EC50 values for selected compounds against hDNMT1 and hDNMT3A have been
determined and are reported in Table 1. The values of SGI-1027 were added for comparison.
Table 1 clearly shows that all the more flexible analogues of 1 (1a–d), obtained by introduction
of a methylene group in different parts of the molecule, as well as the reverse amide 1e and the amine

Cancers 2020, 12, 447
8 of 20
1f displayed much lower hDNMT1 inhibiting potency than 1, and also against hDNMT3A 1a–f
showed a drop of 17 to 73-fold of inhibition. Differently, the bis-quinoline regioisomers 2a–c exhibited
comparable inhibition towards hDNMT1 as 2, and gained potency against hDNMT3A, with the meta–
meta isomer 2b being the most potent (EC50 = 0.8 µM).
Table 1. hDNMT1 and -3A inhibition and antiproliferative activity in U937 AML and HL60 APL cells
for 1a–f, 2a–c, 3a–c, and 4a–c. SGI-1027 and 1–4 were added as reference compounds.
1
2
Enzyme Inhibition (EC50 ± SD, µM)
Antiproliferative Activity (IC50 ± SD, µM)
Compd
hDNMT1
10 ± 1
hDNMT3A
0.8 ± 0.1
0.7 ± 0.5
21.0 ± 3.1
19.0 ± 2.0
31.0 ± 6.0
51.0 ± 10.0
21.0 ± 4.0
12.0 ± 3.0
27.0 ± 5.0
6.0 ± 1.0
0.8 ± 0.1
5.6 ± 1.0
18.0 ± 2.0
41.0 ± 10.0
>100
U937
0.70 ± 0.08
6.90 ± 0.8
1.40 ± 0.2
37.0 ± 5.9
25.8 ± 3.2
67.0 ± 8.8
4.8 ± 0.6
4.4 ± 0.7
6.6 ± 0.9
0.70 ± 0.09
1.5 ± 0.1
1.5 ± 0.1
HL60
3
SGI-1027
0.70 ± 0.16
5.90 ± 0.7
18.1 ± 2.4
40.0 ± 5.0
36.0 ± 4.0
67.0 ± 7.4
9.9 ± 1.1
1 3
1a
1b
1c
1d
1e
1f
5.7 ± 0.2
4
ND
ND
35 ± 7
ND
ND
ND
33 ± 1
23 ± 4
27 ± 5
22 ± 3
68 ± 4
ND
1.9 ± 0.1
5
2
65.0 ± 8.1
0.20 ± 0.03
1.6 ± 0.2
2a
2b
2c
1.9 ± 0.3
5
3
60.0 ± 8.2
52.4 ± 7.6
123.0 ± 15.0
66.0 ± 9.2
2.3 ± 0.4
119.0 ± 12.9
83.0 ± 10.2
225.0 ± 28.5
125.0 ± 16.2
8.3 ± 1.0
3a
3b
3c
ND
ND
67 ± 4
ND
13.0 ± 0.9
17.0 ± 3.0
>32
6
4
7
4a
0.50 ± 0.08
0.30 ± 0.06
4b
4c
ND
ND
13.0 ± 1.4
6.1 ± 1.0
3.2 ± 0.6
1.2 ± 0.2
1.9 ± 0.3
0.30 ± 0.07
1 Data are the mean of at least two independent experiments. 2 Data are the mean of three independent
experiments. 3 Reference [27]. 4 ND, not determined. 5 Reference [26]. 6 Reference [29]. 7 Precipitation
occurred in the medium.
In the case of the bis-pyrimidine analogues, 3a and 3b were less potent or totally inactive against
both the hDNMTs with respect to 3, while the para-meta isomer 3c showed slightly higher hDNMT3A
inhibition. Finally, the Z-containing 4a–c were less effective than 4 against hDNMT1, and against
hDNMT3A the meta-para isomer 4a displayed a drop of potency, maybe due at least in part to
solubility issue, while the para-meta analog 4c was 3-fold more potent.
In addition to enzyme assays, the antiproliferative activities of 1a–f, 2a–c, 3a–c, and 4a–c against
the U937 AML and HL60 APL cell lines have been determined by the MTT method after 48 h
treatment (Table 1). IC50 values for SGI-1027 and 1–4, used as reference compounds, are reported for
comparison. Among the analogues of 1, in U937 cells 1a displayed 5-fold higher potency than 1 in
growth arrest induction, while 1e and 1f exhibited just little increase of potency (1.4/1.5-fold). Against
HL60 cells, only 1f was more effective than 1. In general, a decrease in DNMT inhibitory potency of
such compounds corresponds to lower effects in block of U937 and/or HL60 cell proliferation.
Consistently, the regioisomers 2a–c and 4b,c, which were more potent than the prototypes 2 and 4
against DNMT3A, showed antiproliferative effects at submicromolar or single-digit micromolar
levels against both the tested leukemia cell lines. In particular, the meta-para isomer 2a provided the
strongest proliferation inhibition in both U937 (IC50 values = 0.7 µM) and HL60 (IC50 values = 0.2 µM)
cells, similar as or better than SGI-1027 and 2. Among the regioisomers of 4, the most potent DNMT
inhibitor 4c is also very potent against the leukemia cell lines (IC50 values = 1.2 (U937) and 0.3 (HL60)
µM). Surprisingly, high potency against both the two tested leukemia cell lines was displayed also
by 4a (IC50 values = 0.5 (U937) and 0.3 (HL60) µM), which showed a drop of inhibition potency against
DNMT3A. This could be due to solubility problems that negatively affected the enzyme assay and/or
to the presence of off-target effects. Differently from 2a–c and 4a–c, the bis-pyrimidines 3a–c were
practically inactive at cellular level (both cell lines), similarly to their reference compound 3.

Cancers 2020, 12, 447
9 of 20
Compounds 2b and 4c, chosen as representative samples of 2a–c and 4a–c, were tested against
peripheral blood B lymphocyte AHH1 cells to assess their differential toxicity. After 48 h treatment,
the two compounds exhibited IC50 values of 3.3 (2b) and 9.6 µM (4c), thus showing 2- to 30-fold
selectivity for arrest of proliferation in leukemia.
2.3. Target Modulation by 2a, 4a, and 4c in KG-1 Leukemia Cells
To check their ability to reactivate gene expression through demethylation in cells, 2a, 4a and 4c
were tested in KG-1 acute myeloid leukemia cells at increasing doses (0.5, 1.0, 5.0, 10.0, and 25.0 µM)
using a stably integrated luciferase reporter system under the control of a cytomegalovirus (CMV)
promoter inhibited by DNA methylation (CMV-luc assay, Table 2), already reported by us [24,29].
SGI-1027 and DAC were used as reference compounds. In this assay, 2a and 4c confirmed their
capability to inhibit DNMTs in cells by strong induction of the luciferase signal starting from 5 µM
(lower reactivation at higher doses is due to high cytotoxicity of compounds against KG-1 cells), while
4a failed in this test confirming its poor (if any) effect on DNMTs. SGI-1027 displayed the same
behavior as 2a and 4c, while DAC was able to reactivate the CMV promoter already at 0.5 µM.
Table 2. Fold induction of the luciferase signal of the CMV-luc construct in KG-1 leukemia cells
treated with 2a, 4a, and 4c. SGI-1027 and DAC were added as reference compounds.
1
Luciferase Expression (Fold ± SD )
Compd
0.5 µM
1 µM
5 µM
10 µM
25 µM
2a
4a
4c
1.02 ± 0.04
1.05 ± 0.12
0.96 ± 0.01
1.07 ± 0.16
1.05 ± 0.12
1.02 ± 0.07
0.87 ± 0.05
1.16 ± 0.20
19.94 ± 4.26
1.04 ± 0.16
40.40 ± 12.75 28.51 ± 3.39 8.07 ± 1.96
25.54 ± 5.77
23.82 ± 5.44
4.66 ± 1.63
1.45 ± 0.39
1.59 ± 0.59
1.60 ± 1.00
SGI-1027
DAC
6.00 ± 2.57
20.96 ± 4.02
3.24 ± 1.66
2
18.13 ± 5.52 19.80 ± 3.88
ND
1 All experiments were performed from n = 2 to n = 4. 2 ND, not determined.
2.4. Compounds 2a–c and 4b Induce Apoptosis in U937 Leukemia Cells
To characterize the mechanism of the 2a–c and 4a–c antiproliferative activities in leukemia U937
cells, we checked for the ability of such compounds to induce apoptosis. U937 cells were treated with
1 µM 2a–c and 4a–c for 24 and 48 h, and the percentages of sub-G1 peaks in their cell cycle profiles
were analyzed as shown in Figure 5. Among the tested compounds, 2a–c as well as 4b induced a
remarkable increase of the sub-G1 peaks when compared to untreated cells, whereas 4a and 4c
exhibited very low (4a) or no (4c) effect in this assay. Notably, 2a–c were the most potent in sub-G1
induction by providing values up to 62% (2a, 48 h), indicating that apoptosis induction is the main
mechanism by which they produce U937 cell proliferation arrest. To confirm this finding, 2a–c were
tested in U937 cells at 1 µM for 24 h to check their abilities to induce caspase 3 activation and annexin-
V-FITC staining. Consistently with the effects observed with sub-G1 peak induction, 2a–c provided
16% to 23% of active caspase 3 induction, as well as 32% to 45% annexin-V-FITC staining positive
cells in U937 cells (Figure 6).

Cancers 2020, 12, 447
10 of 20
Figure 5. (A) Percentage of sub-G1 peaks in U937 cells after treatment with 2a–c, 4a–c and their
respective references compounds 2 and 4, all tested at 1 µM for 24 and 48 h. (B) FACS panel relative
to the sub-G1 peaks.
Figure 6. (A) Compounds 2a–c induced caspase 3 activation (up) and annexin V-FITC staining
positive cells (down) in U937 cells after treatment at 1 µM for 24 h. (B) Percentage of fraction of cells
in life, early apoptosis, secondary necrosis, and necrosis.
2.5. Effects of 2a–c and 4a–c on Solid Cancer Cell Proliferation
We selected 2a–c and 4a–c to evaluate their capability to affect cell growth in a panel of solid
cancer cell lines from different origins, i.e., H1299 human non-small cell lung carcinoma, HCT116
human colorectal carcinoma, HeLa epithelial cervix carcinoma, M14 human melanoma, HT1080
human fibrosarcoma, and MCF-7 human breast adenocarcinoma, after 48 h treatment using the MTT
method (Table 3). In these assays, the three bis-quinoline isomers 2a–c exhibited higher potency than
the prototype 2, displaying IC50 values ranging from 0.14 (2a, HeLa cells) to 15 (2a, H1299 cells) µM
(IC50 values for 2: from 11 (H1299 cells) to 80 (M14 cells) µM). In particular, 2a and 2b showed a
general better profile in terms of potency against solid cancer cells, 2a displaying submicromolar IC50
values against four cancer cell lines (HCT116, HeLa, M14, HT1080) out of six, and 2b exhibiting the
highest potency (IC50 = 0.3 µM) against MCF-7 cells, correlating with the strongest inhibition of
DNMTs. Differently, among 4a–c, only 4c exerted single-digit micromolar potency against three out
of four tested cell lines (HeLa, M14, and HT1080), the others being markedly less effective, in
agreement with a weaker DNMT3A inhibition activity.

Cancers 2020, 12, 447
11 of 20
Table 3. Antiproliferative IC50 values of compounds 2a–c, 4a–c and their respective reference
compounds 2 and 4 against a panel of solid cancer cell lines.
1
Antiproliferative Activity (IC50 ± SD, µM)
Compd
H1299
11.4 ± 1.8 13.3 ± 2.1
HCT116
HeLa
52.0 ± 5.7
M14
80.0 ± 9.1
HT1080
17.0 ± 2.1
MCF-7
ND
2
2
2a
2b
2c
4
4a
4b
4c
14.7 ± 2.3
5.3 ± 0.9
14.0 ± 1.8
5.9 ± 0.8
45.0 ± 4.1 23.9 ± 2.6
40.0 ± 4.8 20.5 ± 2.8
1.0 ± 0.2
1.5 ± 0.3
2.3 ± 0.5
8.6 ± 1.0
0.14 ± 0.04 0.50 ± 0.08 0.50 ± 0.09
4.1 ± 0.7
0.30 ± 0.06
2.2 ± 0.4
ND
2.0 ± 0.3
4.2 ± 0.8
3.2 ± 0.5
77.0 ± 7.9
65.0 ± 7.3
7.4 ± 1.2
4.7 ± 0.6
3.8 ± 0.7
2.9 ± 0.4
69.0 ± 8.1
15.3 ± 2.0
4.5 ± 0.8
2.7 ± 0.4
2.6 ± 0.6
1.7 ± 0.2
19.5 ± 2.8
13.1 ± 1.5
3.9 ± 0.8
ND
ND
ND
6.9 ± 0.9
17.7 ± 2.4
1 Data are the mean of at least three independent experiments. 2 ND, not detected.
2.6. Target Modulation by 2a–c and 4a–c in HCT116 Cells
Demethylating activity of 2a–c and 4a–c compounds was also evaluated in HCT116 cells
transfected with methylated UCHL1 promoter (pUCHL1, [29,30]). Cells were treated for five days
with 2a–c and 4a–c (all at 0.5 µM, except for 2c used at 0.1 µM) and with the positive controls DAC
(5 µM) and SGI-1027 (0.5 µM). Fluorescence signal was detected as a measure of demethylating
capability. Both fluorescence imaging of live cells and FACS analyses (Figure 7) showed that the
treatment with all the tested compounds caused a strong demethylation of pUCHL1, leading to a
robust induction of EGFP expression. Specifically, the bis-quinoline isomers 2a–c showed an
important demethylation activity around 40%, with 2c displaying the highest potency (42.3%) at the
lowest concentration (0.1 µM). Notably, the demethylation capability of 2a–c was more effective than
SGI-1027 (32.9%) used at the same concentration, and similar to DAC (46.6%) used at 10-fold higher
concentration. Similar effects were observed for 4a–c. Among them, 4c was the strongest
demethylating compound with a value of 58.7%, accounting for its high DNMT3A inhibition
capability shown in the in vitro enzyme assay.

Cancers 2020, 12, 447
12 of 20
Figure 7. Compounds 2a–c and 4a–c display DNA demethylating activity in human HCT116 colon
cancer cells. DAPI (up, blue pictures), fluorescence imaging (up, green pictures) and FACS evaluation
(down) of HCT116 cells transfected with methylated pUCHL1 vector and treated for five days with
DMSO as a vehicle control (Ctr), with DAC (5 µM) and SGI-1027 (0.5 µM) as reference compounds,
and with 2a,b and 4a–c used at 0.5 µM, and 2c used at 0.1 µM.
2.7. Selected Compounds 2b and 4c Induce a Downregulation of DNMT Proteins
Prompted by the evidence that 1 decreased DNMT expression in primary osteosarcoma cells
[28], and 4 phenocopied similar effects in HCT116 and PC-3 cells [29], we tested selected compounds
2b and 4c as representative samples of the 2 and 4 series to study their effects on DNMT1 and
DNMT3A protein expression. In this regard, HCT116 cells were treated with vehicle (DMSO) or with
2b or 4c at different doses (0.1 and 1 µM) for 24 h, and the protein samples were analyzed by western

Cancers 2020, 12, 447
13 of 20
blot. Figure 8A shows that the treatment with the two compounds induced a decrease of both DNMT1
and DNMT3A protein levels at 1 µM, with a higher effect on DNMT3A with respect to DNMT1. This
result correlates with the greater inhibition potency of the compounds against the DNMT3A isoform.
Compound 4c showed the strongest effect against DNMT3A, since a decrease of the protein
expression is detectable also at the lowest dose (0.1 µM). To investigate the mechanism related to this
DNMT downregulation, HCT116 cells were treated with 4c (1 µM) alone or in combination with the
proteasome inhibitor bortezomib (10 nM). The western blot analysis (Figure 8B) clearly shows that
the 4c-dependent decrease of DNMT protein levels occurred via proteasome degradation, since the
addition of bortezomib rescued the expression of both the DNMT proteins.
Figure 8. (A) Left: Western blot analysis of DNMT1 and DNMT3A protein expression levels in
HCT116 cells exposed for 24 h to the indicated concentrations of 2b or 4c. Control cells were treated
with the same volume of vehicle (DMSO). GAPDH was used as loading control. Blots are
representative of two independent experiments. Right: Densitometric analysis of protein levels is
reported. (B) Left: Western blot analysis of DNMT1 and DNMT3A protein expression levels in
HCT116 cells exposed for 24 h to 4c at 1 µM and co-treated with bortezomib (when indicated) used
at 10 nM. Control cells were treated with the same volume of vehicle (DMSO). GAPDH was used as
a loading control. Blots are representative of three independent experiments. Right: Densitometric
analysis of protein levels is reported. Data are represented as mean ± SEM. Significance is represented
as *p < 0.05 related to the control.
2.8. Off-Target Effects: Potential DNA G-Quadruplex (G4) Stabilization and Kinase Inhibition
In addition to the capability to downregulate DNMT proteins, 2a–c and 4a–c were tested to
evaluate their eventual DNA G4 stabilizing properties, in analogy to some quinoline compounds
reported to bind and stabilize DNA G4 regions involved in repression of transcription at the promoter
of oncogenes [31–34]. Compounds 2a–c and 4a–c were tested at 5 and 10 µM by fluorescence
resonance energy transfer (FRET) method with two DNA sequences (F21T and KRAS21R). TMPyP4
[35] (1 µM) was used as the positive control, and SGI-1027, 2 and 4 were added for comparison.
However, none of the new compounds displayed a noteworthy increase of the G4-DNA stabilization
temperatures (ΔTm values) up to 10 µM (Tables S2 and S3 in Supplementary Materials), thus ruling
out the G4 binding as an off-target effect for 2a–c and 4a–c.
Since the quinoline nucleus is a well-known privileged scaffold for human kinases inhibition
[36], the bis-quinoline meta-meta isomer 2b was tested against a panel of 45 human kinases at fixed 10

Cancers 2020, 12, 447
14 of 20
µM dose, to explore if inhibition of kinases could represent an additional effect for its antiproliferative
and pro-apoptotic properties (Table S4 in Supplementary Materials). The results indicated that 2b
inhibited at values ranging from 70% to 98% the biochemical activity of IKK-α (70%), IRK (86%), PKC-
β (79%), RAF-1 (79%), Src (94%), TRKA (98%) kinases, all of them found involved in leukemia
initiation and development [37–42]. This effect, together with DNMT inhibition and induction of
protein degradation, could contribute to explain the potency of 2b in proliferation arrest and
apoptosis induction.
3. Discussion
Starting from the template of SGI-1027 [21], a reliable non-nucleoside DNMTi effective against
cancer, we previously identified the regioisomer (meta-meta isomer) 1 [26,28], the bis-quinoline 2 and
the bis-pyrimidine 3 [[26] analogues as well as compound 4, in which the Z-group replaced the SGI-
1027 pyrimidine moiety [29] as new DNMTi active in cancer cells. Here, we report the design,
synthesis, and antileukemia (U937 AML and HL60 APL cells) activities of a series of less rigid
derivatives of 1, compounds 1a–d, obtained by insertion of a methylene spacer in various points of
the molecule of 1, joined to the reverse amide 1e and the amine 1f. Afterwards, we prepared and
tested in leukemia some regioisomers of 2–4, specifically 2a–c, 3a–c, and 4a–c, in which a meta-para
(a), meta-meta (b), or para-meta (c) linkage has been applied between the two main moieties of the
respective prototypes. Among the new compounds 1a–f, 2a–c, 3a–c, and 4a–c, only the bis-quinoline
2a–c and the Z-containing 4b,c regioisomers displayed remarkable DNMT (DNMT3A) inhibition and
strong antiproliferative effect in U937 and HL60 cells. Compound 4a, although less potent against
DNMT3A in enzyme assay, exhibited high leukemia cells’ growth arrest. In U937 cells, this arrest of
proliferation was mainly due to induction of apoptosis, as demonstrated by the high sub-G1 peaks
shown by U937 cells treated with 2a–c and 4b, and by induction of caspase 3 activation and annexin-
V-FITC staining positive cells from 2a–c in the same cell line. When tested against a panel of solid
cancer cell lines, 2a–c exhibited cell growth arrest at low to submicromolar levels, whereas 4a–c were
less effective. In colon HCT116 cells, 2a–c and 4a–c induced EGFP gene expression through UCHL1
promoter demethylation from 37.7% to 58.7%, demonstrating their demethylating activity in cells.
Finally, 2b and 4c, chosen as prototypes of the bis-quinoline and Z-containing isomers series, have
been proved to induce DNMT, mainly DNMT3A, protein degradation in HCT116 cells with a
proteasome-dependent effect, since the combination of 4c with bortezomib, a proteasome inhibitor,
rescued in part the decrease of the DNMT protein levels.
4. Materials and Methods
4.1. Chemistry
Melting points were determined on a Buchi 530 melting point apparatus and are uncorrected.
H NMR spectra were recorded at 400 MHz on a Bruker AC 400 spectrometer; chemical shifts are
1
reported in δ (ppm) units relative to the internal reference tetramethylsilane (Me4Si). All compounds
1
were routinely checked by TLC and H NMR. TLC was performed on aluminum-backed silica gel
plates (Merck DC, Alufolien Kieselgel 60 F254) with spots visualized by UV light. All solvents were
reagent grade and, when necessary, were purified and dried by standard methods. Concentration of
solutions after reactions and extractions involved the use of a rotary evaporator operating at reduced
pressure of ca. 20 Torr. Organic solutions were dried over anhydrous sodium sulfate. Elemental
analysis has been used to determine the purity of the final compounds 1a–f, 2a–c, 3a–c, and 4a–c, that
is >95%. Analytical results are within ±0.40% of the theoretical values (Table S1, Supplementary
Materials). All chemicals were purchased from Sigma-Aldrich, Milan (Italy), or from Alfa Aesar,
Karlsruhe (Germany), and were of the highest purity. All the chemical procedures are reported as
Supplementary Materials.
4.2. DNA Methyltransferase Assays.

Cancers 2020, 12, 447
15 of 20
4.2.1. DNMT1 Assay
His-DNMT1 (182 kDa, human) was cloned, expressed, and purified as described by Lee et al.
[43]. The DNMT1 assay was performed according to Gros et al. [44]. Briefly, the reaction is performed
with DNMT1 (90 nM in a total volume of 10 µL) treated with the inhibitors used at the desired
3
concentration, 1.25 µM of SAM/[methyl- H] SAM (3TBq/mmol) mix in a ratio of 3:1, and 0.3 µM of
biotinylated DNA duplex. The reaction was incubated 2 h at 37 °C, then 8 µL of the solution are
transferred into a streptavidin 96-well scintillant coated Flashplate containing 190 µL of 20 mM SAH
in 50 mM Tris–HCl (pH 7.4). The Flashplate is agitated for 1 h at room temperature and washed. The
plate is read with TopCount (PerkinElmer). In this assay, the negative and positive controls were
defined as wells without enzyme and wells with only DMSO, respectively.
4.2.2. DNMT3A Assay
DNMT3A enzyme inhibition was adapted from the restriction-based fluorescence assay protocol
described in Ceccaldi et al. [45]. Briefly, a biotin-labelled oligonucleotide at the 5' end is hybridized
to his complementary strand labelled at the 3' end with 6-carboxyfluorescein. The DNA duplex
containing only one single CpG site overlapping with a restriction site of a methylation sensitive
restriction enzyme is transferred in the wells coated with avidin. The methylation reaction is
performed by adding human C-terminal DNMT3A at the final concentration of 4 ng/µL in a total
volume of 50 µL in the presence of the inhibitors at various concentrations and the co-substrate SAM
at the final concentration of 20 µM. The plate was incubated for 1 h at 37 °C, washed, and added with
the methylation sensitive restriction enzyme HpyCH4IV, incubated for 1 h further at 37 °C, washed
and the fluorescence measured with a PerkinElmer Envision Multilabel Plate Reader. The data are
expressed as percentage of inhibition vs. log concentration (M). Data are normalized referring to the
“restriction control” (wells coated with labelled duplex not treated nor exposed to DNMT3A, but
only cleaved by HpyCH4IV) as the maximum of inhibition (100%) and to the “DMSO control” (wells
coated with labelled duplex but treated just with 0.1% DMSO exposed to DNMT3A and then to
HpyCH4IV) as the minimum of inhibition (0%; total methylation).
4.3. CMV-luc Assay in KG-1 Cells
The assay was carried out as described by Rilova et al. [46]. The KG-1 cell line was stably
+
transfected with the luciferase firefly (Luc from pGL3 by Promega, Madison, WI, USA) reporter gene
under the control of a methylated CMV promoter (from pEGFP-N1 by Clontech) and selected for the
maintenance of the methylation of CMV and luciferase expression silencing (KG-1 CMV-luc). The
stably integrated KG-1 CMV-luc cells are cultivated in RPMI-1640 medium (Lonza, Strasbourg,
France), supplemented with 10% FCS (Lonza, Strasbourg, France) and 0.5 mg/mL of geneticin (Sigma-
Aldrich, Saint-Quentin Fallavier, France), under 5% CO2, at 37 °C and seeded at 20,000 cells per well
in 96-well plates. After 5 or 24 h of incubation in the presence of compounds or the solvent DMSO,
the induction of the promoter is measured by quantification of luciferase with the Brite-lite assay
system (PerkinElmer, Villebon-sur-Yvette, France) according to the manufacturer’s protocol. The
luminescence is measured on an EnVision Multilabel Plate Reader (PerkinElmer, Villebon-sur-Yvette,
France), and the data are expressed as fold induction compared to DMSO control. The mean of 2–4
experiments and its standard error are reported.
4.4. UCHL1 Promoter Demethylation Assay (Luciferase Activity Induction) in HCT116 Colon Cancer Cells
The assay was performed as described in [29]. Briefly, human colon cancer HCT116 (ATCC, VA,
USA) cells were grown in Dulbecco’s Modified Eagle Medium (DMEM; Euroclone, Milan, Italy)
supplemented with 10% fetal bovine serum (FBS; Euroclone, Milan, Italy), 2 mM L-glutamine
(Euroclone), and antibiotics (100 U/mL penicillin, 100 g/mL streptomycin) (Euroclone). The pUMLIEP
vector (composed by MetLuc-IRES-EGFP construct upon the control of the ubiquitin carboxyl-
terminal hydrolase L1 (UCHL1)) was linearized and methylated by with ClaI and SssI-methylase
enzymes (New England Biolabs, Milan, Italy). After, methylated pUMLIEP was transfected into

Cancers 2020, 12, 447
16 of 20
HCT116 cells following the protocol described in [30]. HCT116 were seeded in 6-well plates in
4
triplicate (2 × 10 per well) and treated every 2 days with 2a-c and 4a–c as well as the relative controls
SGI-1027 and DAC, changing the medium. On day 5, cells were observed under by a fluorescent
microscope (Cytation 5 Cell Imaging Multi-Mode Reader (BioTeK Milan, Italy) and BD Accuri flow
cytometers. Nuclei were counterstained with DAPI (10 µg/mL, Invitrogen, Tournai, Belgium).
4.5. Antiproliferative Assays
4.5.1. Cell Lines and Culture Conditions
U937 histiocytic lymphoma, HL60 acute promyelocytic leukemia, H1299 lung adenocarcinoma,
MCF7 breast carcinoma, HT1080 fibrosarcoma, M14 melanoma, HeLa epithelial cervix carcinoma and
peripheral blood B lymphocyte AHH1 human cell lines were obtained from the Deutsche Sammlung
für Mikroorganismen and Zellkulturen (DSZM, Braunschweig, Germany) and were maintained in
RPMI 1640 medium contained 10% fetal bovine serum (FBS), 2 mM L-glutamine, and antibiotics in a
humidified atmosphere with 5% CO2 at 37 °C. HCT116 (ATCC, VA, USA) cells were propagated in
Dulbecco’s modified Eagle medium (DMEM) (Euroclone, Milan, Italy) with 10% fetal bovine serum
(FBS; Euroclone, Milan, Italy), 2 mM L-glutamine (Euroclone, Milan, Italy), and antibiotics (100 U/mL
penicillin, 100 g/mL streptomycin) (Euroclone, Milan, Italy). The experiments were performed with
early (3–20) cell passages. Cell lines were treated with compounds at the indicated concentrations in
the exponential growth phase.
4.5.2. Cell Proliferation Experiments
To calculate the dose of a compound that causes 50% of cell growth inhibition (IC50),
3
exponentially growing cells were seeded in 96-well plates (2 × 10 cells/well) and incubated for 72 h
in complete medium. Then, increasing concentrations of different compounds (ranging from 0.01 to
100 µM) were added, and cell proliferation was evaluated by a MTT assay after 48 h. Cells exposed
to DMSO were used as control. The effect of compounds was evaluated using the CellTiter-Glo
luminescent cell viability assay (Promega, Madison, WI, USA) according to the manufacturer’s
4
instructions. For HCT116, 5 × 10 cells/well were plated in 24-well plate and treated, in duplicate, with
compounds at several concentrations for 24 and 48 h of induction. After treatments, MTT solution
was added for 3 h at 0.5 mg/mL, the obtained crystals were dissolved in DMSO (Sigma-Aldrich,
Milan, Italy), and the absorbance was read at a wavelength of 570 nm with reader TECAN M-200. All
the experiments were performed in triplicate and repeated at least three times.
4.5.3. IC50 Values Determination and Statistical Analyses
IC50 values of compounds against cellular viability were determined by using nonlinear
regression fitting curves with GraphPad Prism 8. The t-test used for statistical analyses was
performed with GraphPad Prism 8. All the tests were one-tailed and a p-value <ꢀ0.05 was considered
statistically significant.
4.6. Flow Cytometric Analysis of Cell Cycle and Apoptosis
5
Cell cycle analysis was performed on 5 × 10 fixed cells resuspended in a RNase A (3 mg/mL)
and propidium iodide (PI) solution (1 mg/mL). Samples were analyzed with a C6 Accuri BD (Becton
Dickinson & Co., San Jose, CA, USA). The percentage of apoptosis was measured analyzing sub-G1
peaks. Apoptotic cell death was also evaluated by using annexin V–fluorescein isothiocyanate (FITC)
apoptosis kit (BD Bioscience) and assayed according to the manufacturer’s instructions. Cells double-
stained for both annexin V and PI were analyzed by flow cytometry. PI was used in conjunction with
annexin V–FITC to distinguish cells in the earlier stages of apoptosis (annexin V-FITC positive, PI
negative) from those in later stages of apoptosis or that were already dead (annexin V–FITC positive,
PI positive). Percentage of cells positive for caspase-3 activation was evaluated by Active Caspase-3
Apoptosis Kit (BD biosciences, Milan, Italy) according to the manufacturer’s instructions.

Cancers 2020, 12, 447
17 of 20
4.7. Western Blot Analyses
Cells were lysed in Laemmli buffer; subsequently the proteins were resolved by sodium dodecyl
sulphate-polyacrylamide gel electrophoresis and transferred to a 0.45 µm nitrocellulose membrane
(Bio-Rad Laboratories, Hercules, CA, USA). The following primary antibodies were used for
immunoblotting: α-DNMT1 (Novus Biologicals, Littleton, CO, USA). α-DNMT3a (SantaCruz Bio-
technologies, CA, USA) and α-GAPDH (Millipore Corp., Bedford, MA USA), used as a loading
control. The immune complexes were detected with horseradish peroxidase-conjugated species-
specific secondary antiserum (Bio-Rad Laboratories, Hercules, CA, USA) then by enhanced
chemiluminescence reaction (Bio-Rad Laboratories, Hercules, CA, USA). Densitometric analysis of
protein expression was performed by using the Fiji-Image J image processing package.
5. Conclusions
The here described bis-quinolines 2a-c and the Z-containing compounds 4a–c represent new
SGI-1027 analogues with two simultaneous different activities: (i) high DNMT3A catalytic inhibition,
and (ii) capability to degrade the DNMT proteins. Such compounds turned out to be highly active
against leukemia (2a–c and 4a–c) and/or solid cancer (2a–c) cell proliferation and are worthy of
further investigation in different cancer contexts.
Supplementary Materials: The following are available online at www.mdpi.com/xxx/s1. Synthetic procedures
and chemical and physical data of new compounds from 1a to 27. Table S1: Elemental analysis of the final
compounds 1a–f, 2a–c, 3a–c, and 4a–c, Experimental procedure for Fluorescence Resonance Energy Transfer
(FRET) melting assay. Table S2: Synthetic oligonucleotides used in FRET experiments. Table S3: ∆Tm values for
G-quadruplex DNA FRET assays (F21T and KRAS). Experimental procedure of kinase inhibitory assays. Table
S4: Screening of compound 2a on a panel of kinases.
Author Contributions: Conceptualization, A.M., S.V., and D.T.; chemistry, C.Z., R.F., G.S., and A.R.; DNMT
enzyme assays, D.P. and P.B.A.; leukemias and solid cancer cell lines’ experiments and apoptosis induction,
T.D.L. and D.T.; cellular methylation assays, F.S., A.N., and L.A.; DNMT protein levels’ experiments, C.B. and
R.S.; G4 melting assays, E.M. and A.P.; data analysis, A.M., S.V., M.T., R.S., P.B.A., D.D.B., D.T., and L.A.;
writing—original draft preparation, C.Z., R.F., S.V., and A.M., writing—review and editing, S.V., P.B.A., D.D.B.,
L.A., D.T., and A.M., funding acquisition, L.A., A.M., D.D.B., and P.B.A. All authors have read and agreed to the
published version of the manuscript.
Funding: This work was supported by PRIN 2016 (prot. 20152TE5PK) (L.A., A.M.), Ricerca Finalizzata 2013 PE-
2013-02355271 (A.M.), the Italian Association for Cancer Research AIRC-19162 (A.M.), AIRC-17217 (L.A.) and
AIRC-18560 (D.D.B.), NIH (n. R01GM114306) (A.M.), VALERE: Vanvitelli per la Ricerca Program (L.A.), FP7-
BLUEPRINT (282510) (L.A., A.M.), the Campania Regional Government Lotta alle Patologie Oncologiche (L.A.),
iCURE (CUP B21c17000030007) (L.A.), Campania Regional Government FASE 2: IDEAL (CUP
B63D18000560007) (L.A.), PlanCancer2014 (P.B.A.) and FCT, Portugal through UID/DTP/04138/2019 (A.P., E.M.)
funds.
Acknowledgments: The authors thank Céline Faux for the DNMT1 inhibition assays.
Conflicts of Interest: The authors declare no conflict of interest.
References
1.
2.
3.
4.
Ehrlich, M. DNA methylation in cancer: Too much, but also too little. Oncogene 2002, 21, 5400–5413,
doi:10.1038/sj.onc.1205651.
Baylin, S.B.; Jones, P.A. A decade of exploring the cancer epigenome-biological and translational
implications. Nat. Rev. Cancer 2011, 11, 726–734, doi:10.1038/nrc3130.
Pan, Y.; Liu, G.; Zhou, F.; Su, B.; Li, Y. DNA methylation profiles in cancer diagnosis and therapeutics. Clin.
Exp. Med. 2018, 18, 1–14, doi:10.1007/s10238-017-0467-0.
Lister, R.; Pelizzola, M.; Dowen, R.H.; Hawkins, R.D.; Hon, G.; Tonti-Filippini, J.; Nery, J.R.; Lee, L.; Ye, Z.;
Ngo, Q.M.; et al. Human DNA methylomes at base resolution show widespread epigenomic differences.
Nature 2009, 462, 315–322, doi:10.1038/nature08514.

Cancers 2020, 12, 447
18 of 20
5.
Laurent, L.; Wong, E.; Li, G.; Huynh, T.; Tsirigos, A.; Ong, C.T.; Low, H.M.; Kin Sung, K.W.; Rigoutsos, I.;
Loring, J.; et al. Dynamic changes in the human methylome during differentiation. Genome Res. 2010, 20,
320–331, doi:10.1101/gr.101907.109.
6.
7.
8.
9.
Portela, A.; Esteller, M. Epigenetic modifications and human disease. Nat. Biotechnol. 2010, 28, 1057–1068,
doi:10.1038/nbt.1685.
Robertson, K.D. DNA methylation, methyltransferases, and cancer. Oncogene 2001, 20, 3139–3155,
doi:10.1038/sj.onc.1204341.
Zwergel, C.; Valente, S.; Mai, A. DNA Methyltransferases Inhibitors from Natural Sources. Curr. Top. Med.
Chem. 2016, 16, 680–696.
Gros, C.; Fahy, J.; Halby, L.; Dufau, I.; Erdmann, A.; Gregoire, J.M.; Ausseil, F.; Vispe, S.; Arimondo, P.B.
DNA methylation inhibitors in cancer: Recent and future approaches. Biochimie 2012, 94, 2280–2296,
doi:10.1016/j.biochi.2012.07.025.
10. Hervouet, E.; Vallette, F.M.; Cartron, P.F. Dnmt1/Transcription factor interactions: An alternative
mechanism of DNA methylation inheritance. Genes. Cancer 2010, 1, 434–443, doi:10.1177/1947601910373794.
11. Wang, J.; Hevi, S.; Kurash, J.K.; Lei, H.; Gay, F.; Bajko, J.; Su, H.; Sun, W.; Chang, H.; Xu, G.; et al. The lysine
demethylase LSD1 (KDM1) is required for maintenance of global DNA methylation. Nat. Genet. 2009, 41,
125–129, doi:10.1038/ng.268.
12. Daniel, F.I.; Cherubini, K.; Yurgel, L.S.; de Figueiredo, M.A.; Salum, F.G. The role of epigenetic transcription
repression and DNA methyltransferases in cancer. Cancer 2011, 117, 677–687, doi:10.1002/cncr.25482.
13. Pechalrieu, D.; Etievant, C.; Arimondo, P.B. DNA methyltransferase inhibitors in cancer: From
pharmacology to translational studies. Biochem. Pharmacol. 2017, 129, 1–13, doi:10.1016/j.bcp.2016.12.004.
14. Yoo, C.B.; Jeong, S.; Egger, G.; Liang, G.; Phiasivongsa, P.; Tang, C.; Redkar, S.; Jones, P.A. Delivery of 5-
aza-2'-deoxycytidine to cells using oligodeoxynucleotides. Cancer Res. 2007, 67, 6400–6408,
doi:10.1158/0008-5472.CAN-07-0251.
15. ClinicalTrials.gov. Availabe online: www.clinicaltrials.gov Search term: DNA methyltransferase AND
inhibition (accessed on 26 June 2019).
16. Castillo-Aguilera, O.; Depreux, P.; Halby, L.; Arimondo, P.B.; Goossens, L. DNA Methylation Targeting:
The DNMT/HMT Crosstalk Challenge. Biomolecules 2017, 7, doi:10.3390/biom7010003.
17. Brueckner, B.; Garcia Boy, R.; Siedlecki, P.; Musch, T.; Kliem, H.C.; Zielenkiewicz, P.; Suhai, S.; Wiessler,
M.; Lyko, F. Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of
human DNA methyltransferases. Cancer Res. 2005, 65, 6305–6311, doi:10.1158/0008-5472.CAN-04-2957.
18. Asgatay, S.; Champion, C.; Marloie, G.; Drujon, T.; Senamaud-Beaufort, C.; Ceccaldi, A.; Erdmann, A.;
Rajavelu, A.; Schambel, P.; Jeltsch, A.; et al. Synthesis and evaluation of analogues of N-phthaloyl-l-
tryptophan (RG108) as inhibitors of DNA methyltransferase 1. J. Med. Chem 2014, 57, 421–434,
doi:10.1021/jm401419p.
19. Castellano, S.; Kuck, D.; Viviano, M.; Yoo, J.; Lopez-Vallejo, F.; Conti, P.; Tamborini, L.; Pinto, A.; Medina-
Franco, J.L.; Sbardella, G. Synthesis and biochemical evaluation of delta(2)-isoxazoline derivatives as DNA
methyltransferase 1 inhibitors. J. Med. Chem. 2011, 54, 7663–7677, doi:10.1021/jm2010404.
20. Castellano, S.; Kuck, D.; Sala, M.; Novellino, E.; Lyko, F.; Sbardella, G. Constrained analogues of procaine
as novel small molecule inhibitors of DNA methyltransferase-1. J. Med. Chem. 2008, 51, 2321–2325,
doi:10.1021/jm7015705.
21. Datta, J.; Ghoshal, K.; Denny, W.A.; Gamage, S.A.; Brooke, D.G.; Phiasivongsa, P.; Redkar, S.; Jacob, S.T. A
new class of quinoline-based DNA hypomethylating agents reactivates tumor suppressor genes by
blocking DNA methyltransferase 1 activity and inducing its degradation. Cancer Res. 2009, 69, 4277–4285,
doi:10.1158/0008-5472.CAN-08-3669.
22. Chen, S.; Wang, Y.; Zhou, W.; Li, S.; Peng, J.; Shi, Z.; Hu, J.; Liu, Y.C.; Ding, H.; Lin, Y.; et al. Identifying
novel selective non-nucleoside DNA methyltransferase 1 inhibitors through docking-based virtual
screening. J. Med. Chem. 2014, 57, 9028–9041, doi:10.1021/jm501134e.
23. Erdmann, A.; Menon, Y.; Gros, C.; Masson, V.; Aussagues, Y.; Ausseil, F.; Novosad, N.; Schambel, P.; Baltas,
M.; Arimondo, P.B. Identification and optimization of hydrazone-gallate derivatives as specific inhibitors
of DNA methyltransferase 3A. Future Med. Chem. 2016, 8, 373–380, doi:10.4155/fmc.15.192.
24. Rotili, D.; Tarantino, D.; Marrocco, B.; Gros, C.; Masson, V.; Poughon, V.; Ausseil, F.; Chang, Y.; Labella, D.;
Cosconati, S.; et al. Properly substituted analogues of BIX-01294 lose inhibition of G9a histone

Cancers 2020, 12, 447
19 of 20
methyltransferase and gain selective anti-DNA methyltransferase 3A activity. PLoS ONE 2014, 9, e96941,
doi:10.1371/journal.pone.0096941.
25. Halby, L.; Menon, Y.; Rilova, E.; Pechalrieu, D.; Masson, V.; Faux, C.; Bouhlel, M.A.; David-Cordonnier,
M.H.; Novosad, N.; Aussagues, Y.; et al. Rational Design of Bisubstrate-Type Analogues as Inhibitors of
DNA
Methyltransferases
in
Cancer
Cells.
J.
Med.
Chem.
2017,
60,
4665–4679,
doi:10.1021/acs.jmedchem.7b00176.
26. Valente, S.; Liu, Y.; Schnekenburger, M.; Zwergel, C.; Cosconati, S.; Gros, C.; Tardugno, M.; Labella, D.;
Florean, C.; Minden, S., et al. Selective non-nucleoside inhibitors of human DNA methyltransferases active
in cancer including in cancer stem cells. J. Med. Chem. 2014, 57, 701–713, doi:10.1021/jm4012627.
27. Gros, C.; Fleury, L.; Nahoum, V.; Faux, C.; Valente, S.; Labella, D.; Cantagrel, F.; Rilova, E.; Bouhlel, M.A.;
David-Cordonnier, M.H.; et al. New insights on the mechanism of quinoline-based DNA Methyltransferase
inhibitors. J. Biol. Chem. 2015, 290, 6293–6302, doi:10.1074/jbc.M114.594671.
28. Manara, M.C.; Valente, S.; Cristalli, C.; Nicoletti, G.; Landuzzi, L.; Zwergel, C.; Mazzone, R.; Stazi, G.;
Arimondo, P.B.; Pasello, M.; et al. A Quinoline-Based DNA Methyltransferase Inhibitor as a Possible
Adjuvant in Osteosarcoma Therapy. Mol. Cancer Ther. 2018, 17, 1881–1892, doi:10.1158/1535-7163.MCT-17-
0818.
29. Zwergel, C.; Schnekenburger, M.; Sarno, F.; Battistelli, C.; Manara, M.C.; Stazi, G.; Mazzone, R.; Fioravanti,
R.; Gros, C.; Ausseil, F.; et al. Identification of a novel quinoline-based DNA demethylating compound
highly potent in cancer cells. Clin. Epigenetics 2019, 11, 68, doi:10.1186/s13148-019-0663-8.
30. Okochi-Takada, E.; Hattori, N.; Ito, A.; Niwa, T.; Wakabayashi, M.; Kimura, K.; Yoshida, M.; Ushijima, T.
Establishment of a high-throughput detection system for DNA demethylating agents. Epigenetics 2018, 13,
147–155, doi:10.1080/15592294.2016.1267887.
31. Shirude, P.S.; Gillies, E.R.; Ladame, S.; Godde, F.; Shin-Ya, K.; Huc, I.; Balasubramanian, S. Macrocyclic and
helical oligoamides as a new class of G-quadruplex ligands. J. Am. Chem. Soc. 2007, 129, 11890–11891,
doi:10.1021/ja073775h.
32. Brito, H.; Martins, A.C.; Lavrado, J.; Mendes, E.; Francisco, A.P.; Santos, S.A.; Ohnmacht, S.A.; Kim, N.S.;
Rodrigues, C.M.; Moreira, R.; et al. Targeting KRAS Oncogene in Colon Cancer Cells with 7-Carboxylate
Indolo
[3,2-b]quinoline
Tri-Alkylamine
Derivatives.
PLoS
ONE
2015,
10,
e0126891,
doi:10.1371/journal.pone.0126891.
33. Lavrado, J.; Brito, H.; Borralho, P.M.; Ohnmacht, S.A.; Kim, N.S.; Leitao, C.; Pisco, S.; Gunaratnam, M.;
Rodrigues, C.M.; Moreira, R.; et al. KRAS oncogene repression in colon cancer cell lines by G-quadruplex
binding indolo[3,2-c]quinolines. Sci. Rep. 2015, 5, 9696, doi:10.1038/srep09696.
34. Zeng, D.Y.; Kuang, G.T.; Wang, S.K.; Peng, W.; Lin, S.L.; Zhang, Q.; Su, X.X.; Hu, M.H.; Wang, H.; Tan, J.H.;
et al. Discovery of Novel 11-Triazole Substituted Benzofuro[3,2-b]quinolone Derivatives as c-myc G-
Quadruplex Specific Stabilizers via Click Chemistry. J. Med. Chem. 2017, 60, 5407–5423,
doi:10.1021/acs.jmedchem.7b00016.
35. Cogoi, S.; Xodo, L.E. G-quadruplex formation within the promoter of the KRAS proto-oncogene and its
effect on transcription. Nucleic Acids Res. 2006, 34, 2536–2549, doi:10.1093/nar/gkl286.
36. Musiol, R. An overview of quinoline as a privileged scaffold in cancer drug discovery. Expert Opin. Drug
Discov. 2017, 12, 583–597, doi:10.1080/17460441.2017.1319357.
37. Hsieh, M.Y.; Van Etten, R.A. IKK-dependent activation of NF-kappaB contributes to myeloid and lymphoid
leukemogenesis by BCR-ABL1. Blood 2014, 123, 2401–2411, doi:10.1182/blood-2014-01-547943.
38. Saiya-Cork, K.; Collins, R.; Parkin, B.; Ouillette, P.; Kuizon, E.; Kujawski, L.; Erba, H.; Campagnaro, E.;
Shedden, K.; Kaminski, M.; et al. A pathobiological role of the insulin receptor in chronic lymphocytic
leukemia. Clin. Cancer Res. 2011, 17, 2679–2692, doi:10.1158/1078-0432.CCR-10-2058.
39. Green, L.J.; Marder, P.; Ray, C.; Cook, C.A.; Jaken, S.; Musib, L.C.; Herbst, R.S.; Carducci, M.; Britten, C.D.;
Basche, M.; et al. Development and validation of a drug activity biomarker that shows target inhibition in
cancer patients receiving enzastaurin, a novel protein kinase C-beta inhibitor. Clin. Cancer Res. 2006, 12,
3408–3415, doi:10.1158/1078-0432.CCR-05-2231.
40. Jamshidi, F.; Zhang, J.; Harrison, J.S.; Wang, X.; Studzinski, G.P. Induction of differentiation of human
leukemia cells by combinations of COX inhibitors and 1,25-dihydroxyvitamin D3 involves Raf1 but not Erk
1/2 signaling. Cell Cycle 2008, 7, 917–924, doi:10.4161/cc.7.7.5620.

Cancers 2020, 12, 447
20 of 20
41. Jensen, H.A.; Styskal, L.E.; Tasseff, R.; Bunaciu, R.P.; Congleton, J.; Varner, J.D.; Yen, A. The Src-family
kinase inhibitor PP2 rescues inducible differentiation events in emergent retinoic acid-resistant
myeloblastic leukemia cells. PLoS ONE 2013, 8, e58621, doi:10.1371/journal.pone.0058621.
42. Kim, M.S.; Kim, G.M.; Choi, Y.J.; Kim, H.J.; Kim, Y.J.; Jin, W. c-Src activation through a TrkA and c-Src
interaction is essential for cell proliferation and hematological malignancies. Biochem. Biophys. Res. Commun.
2013, 441, 431–437, doi:10.1016/j.bbrc.2013.10.082.
43. Lee, B.H.; Yegnasubramanian, S.; Lin, X.; Nelson, W.G. Procainamide is a specific inhibitor of DNA
methyltransferase 1. J. Biol. Chem. 2005, 280, 40749–40756, doi:10.1074/jbc.M505593200.
44. Gros, C.; Chauvigne, L.; Poulet, A.; Menon, Y.; Ausseil, F.; Dufau, I.; Arimondo, P.B. Development of a
universal radioactive DNA methyltransferase inhibition test for high-throughput screening and
mechanistic studies. Nucleic Acids Res. 2013, 41, e185, doi:10.1093/nar/gkt753.
45. Ceccaldi, A.; Rajavelu, A.; Champion, C.; Rampon, C.; Jurkowska, R.; Jankevicius, G.; Senamaud-Beaufort,
C.; Ponger, L.; Gagey, N.; Ali, H.D.; et al. C5-DNA methyltransferase inhibitors: From screening to effects
on zebrafish embryo development. Chembiochem 2011, 12, 1337–1345, doi:10.1002/cbic.201100130.
46. Rilova, E.; Erdmann, A.; Gros, C.; Masson, V.; Aussagues, Y.; Poughon-Cassabois, V.; Rajavelu, A.; Jeltsch,
A.; Menon, Y.; Novosad, N.; et al. Design, synthesis and biological evaluation of 4-amino-N- (4-
aminophenyl)benzamide analogues of quinoline-based SGI-1027 as inhibitors of DNA methylation.
ChemMedChem 2014, 9, 590–601, doi:10.1002/cmdc.201300420.
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).